Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 12, 2009, Pages 4679-4687

  Hare, Kristine J ^a,b   Knop, Filip K ^b   Asmar, Meena ^a   Madsbad, Sten ^b   Deacon, Carolyn F ^a   Holst, Jens J ^a   Vilsbøll, Tina ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLITAZONE DERIVATIVE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; METFORMIN; METFORMIN PLUS SITAGLIPTIN; NEUTRAL INSULIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHEMOSENSITIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE DURATION; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG POTENCY; FEMALE; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HORMONE INHIBITION; HUMAN; INSULIN INFUSION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET ALPHA CELL; PRIORITY JOURNAL;

EID: 73249122913     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-0921     Document Type: Article

References (46)

1. Kahn SE 2003 The relative contributions of insulin resistance and β-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 46:3-19
2. Pratley RE, Weyer C 2001 The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia 44:929-945
3. Unger RH, Orci L 1981 Glucagon and the A cell: physiology and pathophysiology (second of two parts). N Engl J Med 304:1575-1580
4. Unger RH, Orci L 1981 Glucagon and the A cell: physiology and pathophysiology (first two parts). N Engl J Med 304:1518-1524
5. Müller WA, Faloona GR, Aguilar-Parada E, Unger RH 1970 Abnormal α-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med 283:109-115
6. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, Holst JJ 2001 Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86:3717-3723
7. Knop FK, Vilsbøll T, Madsbad S, Holst JJ, Krarup T 2007 Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia 50:797-805
8. Ahrén B, Larsson H 2001 Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations. Diabetologia 44:1998-2003
9. Dobbs R, Sakurai H, Sasaki H, Faloona G, Valverde I, Baetens D, Orci L, Unger R 1975 Glucagon: role in the hyperglycemia of diabetes mellitus. Science 187:544-547
10. Gerich JE, Lorenzi M, Karam JH, Schneider V, Forsham PH 1975 Abnormal pancreatic glucagon secretion and postprandial hyperglycemia in diabetes mellitus. JAMA 234:159-155
11. Unger RH, Orci L 1975 The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1:14-16
12. UngerRH1978 Role of glucagon in the pathogenesis of diabetes: the status of the controversy. Metabolism 27:1691-1709
13. Cherrington AD, Chiasson JL, Liljenquist JE, Lacy WW, Park CR 1978 Control of hepatic glucose output by glucagon and insulin in the intact dog. Biochem Soc Symp 43:31-45
14. Jiang G, Zhang BB 2003 Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab 284:E671-E678
15. Shah P, Basu A, Basu R, Rizza R 1999 Impact of lack of suppression of glucagon on glucose tolerance in humans. Am J Physiol 277:E283-E290
16. Fehmann HC, Göke R, Göke B 1995 Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev 16:390-410
17. Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, Hüfner M, SchmiegelWH2002 Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 87:1239-1246
18. Ritzel R, Orskov C, Holst JJ, Nauck MA 1995 Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Doseresponse-relationships. Diabetologia 38:720-725
19. Zander M, Madsbad S, Madsen JL, Holst JJ 2002 Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824-830
20. Zhou J,WangX, PineyroMA,EganJM1999 Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes 48:2358-2366
21. Orskov C, Holst JJ, Nielsen OV 1988 Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 123:2009-2013
22. Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, Nauck MA 2003 Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 88:2719-2725
23. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, CreutzfeldtW1993 Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301-307
24. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, CreutzfeldtW 1993 Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741-744
25. Toft-Nielsen MB, Madsbad S, Holst JJ 1999 Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22:1137-1143
26. Deacon CF, Carr RD, Holst JJ 2008 DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes. Front Biosci 13:1780-1794
27. Kjems LL, Holst JJ, Vølund A, Madsbad S 2003 The influence of GLP-1 on glucose-stimulated insulin secretion: effects on β-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52:380-386
28. Højberg PV, Zander M, Vilsbøll T, Knop FK, Krarup T, Vølund A, Holst JJ, Madsbad S 2008 Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes. Diabetologia 51:632-640
29. Nauck MA, Blietz RW, Qualmann C 1996 Comparison of hyperinsulinaemic clamp experiments using venous, 'arterialized' venous or capillary euglycaemia. Clin Physiol 16:589-602
30. Wise SD, Nielsen MF, Cryer PE, Rizza RA 1998 Overnight normalization of glucose concentrations improves hepatic but not extrahepatic insulin action in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 83:2461-2469
31. Bablok W, Passing H, Bender R, Schneider B 1988 A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. J Clin Chem Clin Biochem 26:783-790
32. Holst JJ 1980 Evidence that glicentin contains the entire sequence of glucagon. Biochem J 187:337-343
33. Orskov C, Wettergren A, Holst JJ 1993 Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 42:658-661
34. Vilsbøll T, Agersø H, Krarup T, Holst JJ 2003 Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 88:220-224
35. Vilsbøll T, Krarup T, Madsbad S, Holst JJ 2002 Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia 45:1111-1119
36. Højberg PV, Vilsbøll T, Rabøl R, Knop FK, Bache M, Krarup T, Holst JJ, Madsbad S 2009 Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 52:199-207
37. Knop FK, Vilsbøll T, Højberg PV, Larsen S, Madsbad S, Vølund A, Holst JJ, Krarup T 2007 Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes 56:1951-1959
38. Shah P, Vella A, Basu A, Basu R, Schwenk WF, RizzaRA2000 Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 85:4053-4059
39. Baron AD, Schaeffer L, Shragg P, Kolterman OG 1987 Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 36:274-283
40. Dunning BE, Gerich JE 2007 The role of α-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev 28:253-283
41. Ishihara H, Maechler P, Gjinovci A, Herrera PL, WollheimCB2003 Islet β-cell secretion determines glucagon release from neighbouring α-cells. Nat Cell Biol 5:330-335
42. Franklin I, Gromada J, Gjinovci A, Theander S, Wollheim CB 2005 β-Cell secretory products activate α-cell ATP-dependent potassium channels to inhibit glucagon release. Diabetes 54:1808-1815
43. Heller RS, Kieffer TJ, Habener JF 1997 Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing α-cells of the rat endocrine pancreas. Diabetes 46:785-791
44. Moens K, Heimberg H, Flamez D, Huypens P, Quartier E, Ling Z, Pipeleers D, Gremlich S, Thorens B, Schuit F 1996 Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. Diabetes 45:257-261
45. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA 1996 Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I (7-36) amide in type I diabetic patients. Diabetes Care 19:580-586
46. de Heer J, Rasmussen C, Coy DH, Holst JJ 2008 Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia 51:2263-2270